Presenter: Paul Anderson, NMD

Original Date: September 24, 2017

What are the basics of “cause” in the areas of agitation and sleep problems. What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous GABA, Glycine and other calming neurotransmitters benefit and refine your therapies?

What are the basics of “cause” in the areas of depression? What (and why) are the common pharmaceuticals used in these cases? How can a knowledge of the genomics of endogenous serotonin, dopamine and norepinephrine neurotransmitters benefit and refine your therapies?

How does the brain become inflamed and how does that affect neuropsychiatric status? What genomic and nutrigenomic factors can alter this status and restore the brain to a non-inflamed state?

Dr. Anderson discusses case studies that he has worked through in neuro-psychiatric conditions and how they played out. The goal of these cases is to illustrate how genomic assessment and nutrigenomics cross over pharmacology and how they can be implemented clinically.

0.5 Pharmacology, 1.0 General (Total 1.5 CEUs) approved by OBNM